{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:55Z","timestamp":1782719095304,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ck0106015h0001"],"award-info":[{"award-number":["JP25ck0106015h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmogo.2026.100322","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:55:07Z","timestamp":1775598907000},"page":"100322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy\u2014phase II investigator-initiated trial (NCCH2412\/MK015)"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8946-6970","authenticated-orcid":false,"given":"H.","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-1419","authenticated-orcid":false,"given":"H.","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-6375","authenticated-orcid":false,"given":"T.","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-6382","authenticated-orcid":false,"given":"K.","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-5227","authenticated-orcid":false,"given":"H.","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3623-6691","authenticated-orcid":false,"given":"T.","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-1248","authenticated-orcid":false,"given":"A.","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6273-6598","authenticated-orcid":false,"given":"M.","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-0876","authenticated-orcid":false,"given":"K.","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2026.100322_bib1","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmogo.2026.100322_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmogo.2026.100322_bib3","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1245\/s10434-011-2173-6","article-title":"A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease","volume":"19","author":"Overman","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmogo.2026.100322_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14694\/EdBook_AM.2013.33.189","article-title":"Rare but real: management of small bowel adenocarcinoma","volume":"33","author":"Overman","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.esmogo.2026.100322_bib5","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmogo.2026.100322_bib6","first-page":"689","article-title":"Efficacy of the FOLFOX\/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China","volume":"16","author":"Zhang","year":"2011","journal-title":"J BUON"},{"key":"10.1016\/j.esmogo.2026.100322_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.esmogo.2026.100322_bib8","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/cncr.30766","article-title":"North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma","volume":"123","author":"McWilliams","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.esmogo.2026.100322_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10147-017-1138-6","article-title":"A phase II study of 5-fluorouracil\/leucovorin\/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma","volume":"22","author":"Horimatsu","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmogo.2026.100322_bib10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmogo.2026.100322_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104098","article-title":"Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis","volume":"10","author":"Fujii","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmogo.2026.100322_bib12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/cpt.1817","article-title":"MASTER KEY Project: powering clinical development for rare cancers through a platform trial","volume":"108","author":"Okuma","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmogo.2026.100322_bib13","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.21873\/anticanres.15332","article-title":"Second-line chemotherapy for previously treated metastatic small bowel adenocarcinoma: a retrospective analysis","volume":"41","author":"Nakazawa","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmogo.2026.100322_bib14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1200\/JCO.2025.43.4_suppl.796","article-title":"Clinical characteristics and treatment outcomes for metastatic early-onset small bowel adenocarcinoma treated with first-line chemotherapy","volume":"43","author":"Yamaguchi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100322_bib15","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmogo.2026.100322_bib16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.25614","article-title":"Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study","volume":"117","author":"Zaanan","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100322_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdx688","article-title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","volume":"29","author":"Overman","year":"2018","journal-title":"Ann Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:52:12Z","timestamp":1782715932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"alternative-id":["S2949819826000221"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100322","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy\u2014phase II investigator-initiated trial (NCCH2412\/MK015)","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100322"}}